Skip to content
2000
Volume 21, Issue 5
  • ISSN: 1573-403X
  • E-ISSN: 1875-6557

Abstract

Introduction

Reducing the risk of atherosclerotic cardiovascular disease is the aim of lipid-lowering therapy (ASCVD). It is commonly acknowledged that low-density lipoprotein (LDL) is a major cause of ASCVD. Several online databases and search engines, such as PubMed and the Cochrane Library, were used to conduct a thorough search.

Methods

This study included RCTs assessing the effect of PCSK9 inhibitors on cardiovascular events. The RevMan 5.4 software was used to conduct the meta-analysis. This analysis included nine RCTs in total.

Results

Meta-analysis of the included studies showed that the levels of total cholesterol, LDL, and triglycerides were reduced after the use of PCSK9 inhibitors, and HDL levels were increased, which is good cholesterol. Most adverse cardiac events (MACE) were reduced after the use of PCSK9 inhibitors.

Conclusion

In conclusion, ezetimibe, a PCSK9 inhibitor added to statin therapy, further reduces MACE risk without affecting all-cause mortality, even though statins already significantly reduce major adverse cardiovascular events (MACE) and mortality.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ccr/10.2174/011573403X345749250122092324
2025-02-11
2025-09-27

  • From This Site

    /content/journals/ccr/10.2174/011573403X345749250122092324
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. BorénJ. ChapmanM.J. KraussR.M. PackardC.J. BentzonJ.F. BinderC.J. DaemenM.J. DemerL.L. HegeleR.A. NichollsS.J. NordestgaardB.G. WattsG.F. BruckertE. FazioS. FerenceB.A. GrahamI. HortonJ.D. LandmesserU. LaufsU. MasanaL. PasterkampG. RaalF.J. RayK.K. SchunkertH. TaskinenM.R. van de SluisB. WiklundO. TokgozogluL. CatapanoA.L. GinsbergH.N. Low-density lipoproteins cause atherosclerotic cardiovascular disease: Pathophysiological, genetic, and therapeutic insights: A consensus statement from the European Atherosclerosis Society Consensus Panel.Eur. Heart J.202041242313233010.1093/eurheartj/ehz96232052833
     [Google Scholar]
  2. KhanS.U. YedlapatiS.H. LoneA.N. HaoQ. GuyattG. DelvauxN. BekkeringG.E.T. VandvikP.O. RiazI.B. LiS. AertgeertsB. RodondiN. PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: A systematic review and network meta-analysis.BMJ2022377e06911610.1136/bmj‑2021‑06911635508321
     [Google Scholar]
  3. HameedI. ShahS.A. AijazA. MushahidH. FarhanS.H. DadaM. KhanA.B. AmjadR. AlviF. MurtazaM. ZuberiZ. HamzaM. Comparative safety and efficacy of low/moderate-intensity statin plus ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease: An updated meta-analysis.Am. J. Cardiovasc. Drugs202424341943110.1007/s40256‑024‑00642‑838578578
     [Google Scholar]
  4. RohE. KoS.H. KwonH.S. KimN.H. KimJ.H. KimC.S. SongK.H. WonJ.C. KimD.J. ChoiS.H. LimS. ChaB.Y. Prevalence and Management of Dyslipidemia in Korea: Korea National Health and Nutrition Examination Survey during 1998 to 2010.Diabetes Metab. J.201337643344910.4093/dmj.2013.37.6.43324404515
     [Google Scholar]
  5. AhY.M. JeongM. ChoiH.D. Comparative safety and efficacy of low- or moderate-intensity statin plus ezetimibe combination therapy and high-intensity statin monotherapy: A meta-analysis of randomized controlled studies.PLoS One2022173e026443710.1371/journal.pone.026443735245303
     [Google Scholar]
  6. BaigentC. BlackwellL. EmbersonJ. HollandL.E. ReithC. BhalaN. PetoR. BarnesE.H. KeechA. SimesJ. CollinsR. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials.Lancet201037697531670168110.1016/S0140‑6736(10)61350‑521067804
     [Google Scholar]
  7. GrundyS.M. StoneN.J. BaileyA.L. BeamC. BirtcherK.K. BlumenthalR.S. BraunL.T. de FerrantiS. Faiella-TommasinoJ. FormanD.E. GoldbergR. HeidenreichP.A. HlatkyM.A. JonesD.W. Lloyd-JonesD. Lopez-PajaresN. NdumeleC.E. OrringerC.E. PeraltaC.A. SaseenJ.J. SmithS.C.Jr SperlingL. ViraniS.S. YeboahJ. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: Executive summary.J. Am. Coll. Cardiol.201973243168320910.1016/j.jacc.2018.11.00230423391
     [Google Scholar]
  8. HurK.Y. MoonM.K. ParkJ.S. KimS.K. LeeS.H. YunJ.S. BaekJ.H. NohJ. LeeB.W. OhT.J. ChonS. YangY.S. SonJ.W. ChoiJ.H. SongK.H. KimN.H. KimS.Y. KimJ.W. RheeS.Y. LeeY.B. JinS.M. KimJ.H. KimC.H. KimD.J. ChunS. RheeE.J. KimH.M. KimH.J. JeeD. KimJ.H. ChoiW.S. LeeE.Y. YoonK.H. KoS.H. 2021 clinical practice guidelines for diabetes mellitus of the Korean Diabetes Association.Diabetes Metab. J.202145446148110.4093/dmj.2021.015634352984
     [Google Scholar]
  9. SampsonU.K. FazioS. LintonM.F. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: The evidence, etiology, and therapeutic challenges.Curr. Atheroscler. Rep.201214111010.1007/s11883‑011‑0219‑722102062
     [Google Scholar]
  10. AndersonT.J. GrégoireJ. PearsonG.J. BarryA.R. CoutureP. DawesM. FrancisG.A. GenestJ.Jr GroverS. GuptaM. HegeleR.A. LauD.C. LeiterL.A. LonnE. ManciniG.B.J. McPhersonR. NguiD. PoirierP. SievenpiperJ.L. StoneJ.A. ThanassoulisG. WardR. 2016 Canadian Cardiovascular Society guidelines for managing dyslipidemia to prevent cardiovascular disease in the adult.Can. J. Cardiol.201632111263128210.1016/j.cjca.2016.07.51027712954
     [Google Scholar]
  11. WongN.D. ZhaoY. QuekR.G.W. BlumenthalR.S. BudoffM.J. CushmanM. GargP. SandfortV. TsaiM. LopezJ.A.G. Residual atherosclerotic cardiovascular disease risk in statin-treated adults: The Multi-Ethnic Study of Atherosclerosis.J. Clin. Lipidol.20171151223123310.1016/j.jacl.2017.06.01528754224
     [Google Scholar]
  12. MachF. BaigentC. CatapanoA.L. KoskinasK.C. CasulaM. BadimonL. ChapmanM.J. De BackerG.G. DelgadoV. FerenceB.A. GrahamI.M. HallidayA. LandmesserU. MihaylovaB. PedersenT.R. RiccardiG. RichterD.J. SabatineM.S. TaskinenM.R. TokgozogluL. WiklundO. MuellerC. DrexelH. AboyansV. CorsiniA. DoehnerW. FarnierM. GiganteB. KayikciogluM. KrstacicG. LambrinouE. LewisB.S. MasipJ. MoulinP. PetersenS. PetronioA.S. PiepoliM.F. PintóX. RäberL. RayK.K. ReinerŽ. RiesenW.F. RoffiM. SchmidJ-P. ShlyakhtoE. SimpsonI.A. StroesE. SudanoI. TselepisA.D. ViigimaaM. VindisC. VonbankA. VrablikM. VrsalovicM. ZamoranoJ.L. ColletJ-P. KoskinasK.C. CasulaM. BadimonL. John ChapmanM. De BackerG.G. DelgadoV. FerenceB.A. GrahamI.M. HallidayA. LandmesserU. MihaylovaB. PedersenT.R. RiccardiG. RichterD.J. SabatineM.S. TaskinenM-R. TokgozogluL. WiklundO. WindeckerS. AboyansV. BaigentC. ColletJ-P. DeanV. DelgadoV. FitzsimonsD. GaleC.P. GrobbeeD. HalvorsenS. HindricksG. IungB. JüniP. KatusH.A. LandmesserU. LeclercqC. LettinoM. LewisB.S. MerkelyB. MuellerC. PetersenS. PetronioA.S. RichterD.J. RoffiM. ShlyakhtoE. SimpsonI.A. Sousa-UvaM. TouyzR.M. NiboucheD. ZelveianP.H. SiostrzonekP. NajafovR. van de BorneP. PojskicB. PostadzhiyanA. KyprisL. ŠpinarJ. LarsenM.L. EldinH.S. ViigimaaM. StrandbergT.E. FerrièresJ. AgladzeR. LaufsU. RallidisL. BajnokL. GudjónssonT. MaherV. HenkinY. GuliziaM.M. MussagaliyevaA. BajraktariG. KerimkulovaA. LatkovskisG. HamouiO. SlapikasR. VisserL. DingliP. IvanovV. BoskovicA. NazziM. VisserenF. MitevskaI. RetterstølK. JankowskiP. Fontes-CarvalhoR. GaitaD. EzhovM. FoscoliM. GigaV. PellaD. FrasZ. de IslaL.P. HagströmE. LehmannR. AbidL. OzdoganO. MitchenkoO. PatelR.S. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.Eur. Heart J.202041111118810.1093/eurheartj/ehz45531504418
     [Google Scholar]
  13. GiuglianoR.P. PedersenT.R. ParkJ.G. De FerrariG.M. GaciongZ.A. CeskaR. TothK. Gouni-BertholdI. Lopez-MirandaJ. SchieleF. MachF. OttB.R. KanevskyE. PinedaA.L. SomaratneR. WassermanS.M. KeechA.C. SeverP.S. SabatineM.S. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: A prespecified secondary analysis of the FOURIER trial.Lancet2017390101061962197110.1016/S0140‑6736(17)32290‑028859947
     [Google Scholar]
  14. RosensonR.S. HegeleR.A. FazioS. CannonC.P. The evolving future of PCSK9 inhibitors.J. Am. Coll. Cardiol.201872331432910.1016/j.jacc.2018.04.05430012326
     [Google Scholar]
  15. StroesE.S. ThompsonP.D. CorsiniA. VladutiuG.D. RaalF.J. RayK.K. RodenM. SteinE. TokgözoğluL. NordestgaardB.G. BruckertE. De BackerG. KraussR.M. LaufsU. SantosR.D. HegeleR.A. HovinghG.K. LeiterL.A. MachF. MärzW. NewmanC.B. WiklundO. JacobsonT.A. CatapanoA.L. ChapmanM.J. GinsbergH.N. StroesE. ThompsonP.D. CorsiniA. VladutiuG.D. RaalF.J. RayK.K. RodenM. SteinE. TokgözoğluL. NordestgaardB.G. BruckertE. KraussR.M. LaufsU. SantosR.D. MärzW. NewmanC.B. John ChapmanM. GinsbergH.N. John ChapmanM. GinsbergH.N. de BackerG. CatapanoA.L. HegeleR.A. Kees HovinghG. JacobsonT.A. LeiterL. MachF. WiklundO. Statin-associated muscle symptoms: Impact on statin therapy—European Atherosclerosis Society consensus panel statement on assessment, etiology, and management.Eur. Heart J.201536171012102210.1093/eurheartj/ehv04325694464
     [Google Scholar]
  16. ShapiroM.D. TavoriH. FazioS. PCSK9.Circ. Res.2018122101420143810.1161/CIRCRESAHA.118.31122729748367
     [Google Scholar]
  17. MoriartyP.M. GibsonC.A. SlaughterM.S. Efficacy and safety of alirocumab and evolocumab in patients with statin intolerance or muscle-related side effects: A systematic review and meta-analysis.Cardiol. Clin.201836220121010.1016/j.ccl.2017.12.009
     [Google Scholar]
  18. NichollsS.J. PuriR. AndersonT. BallantyneC.M. ChoL. KasteleinJ.J.P. KoenigW. SomaratneR. KassahunH. YangJ. WassermanS.M. ScottR. UngiI. PodolecJ. OphuisA.O. CornelJ.H. BorgmanM. BrennanD.M. NissenS.E. Effect of evolocumab on progression of coronary disease in statin-treated patients: The GLAGOV randomized clinical trial.JAMA2016316222373238410.1001/jama.2016.1695127846344
     [Google Scholar]
  19. KoskinasK.C. WindeckerS. RäberL. Proprotein convertase subtilisin/kexin type 9 inhibition: Insights from clinical trials and future perspectives.Circulation2018137222218223010.1161/CIRCULATIONAHA.117.030330
     [Google Scholar]
  20. SchwartzG.G. BessacL. BerdanL.G. Effect of alirocumab added to high-intensity statin therapy on cardiovascular outcomes in patients with acute coronary syndrome: ODYSSEY OUTCOMES trial.Circulation2018138232401241110.1161/CIRCULATIONAHA.118.038840
     [Google Scholar]
  21. KorenM.J. SabatineM.S. GiuglianoR.P. Long-term efficacy and safety of deficient levels of low-density lipoprotein cholesterol: A review of the PCSK9 inhibitor evolocumab.J. Am. Heart Assoc.2017612e00701910.1161/JAHA.117.007019
     [Google Scholar]
  22. HajarR PCSK 9 inhibitors: A short history and a new era of lipid-lowering therapy.Heart Views2019202747510.4103/HEARTVIEWS.HEARTVIEWS_59_19
     [Google Scholar]
  23. ElguindyA. YacoubM.H. The discovery of PCSK9 inhibitors: A tale of creativity and multifaceted translational research.Glob. Cardiol. Sci. Pract.2013201343910.5339/gcsp.2013.3924749106
     [Google Scholar]
  24. LerenT.P. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia.Clin. Genet.200465541942210.1111/j.0009‑9163.2004.0238.x15099351
     [Google Scholar]
  25. FerenceB.A. GinsbergH.N. GrahamI. RayK.K. PackardC.J. BruckertE. HegeleR.A. KraussR.M. RaalF.J. SchunkertH. WattsG.F. BorénJ. FazioS. HortonJ.D. MasanaL. NichollsS.J. NordestgaardB.G. van de SluisB. TaskinenM.R. TokgözoğluL. LandmesserU. LaufsU. WiklundO. StockJ.K. ChapmanM.J. CatapanoA.L. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.Eur. Heart J.201738322459247210.1093/eurheartj/ehx14428444290
     [Google Scholar]
  26. ArsenaultB.J. PetridesF. TardifJ.C. Emerging treatment options for hypercholesterolemia.Nat. Rev. Cardiol.20211829911110.1038/s41569‑020‑00464‑y
     [Google Scholar]
  27. RidkerP.M. EverettB.M. PradhanA. Low-density lipoprotein cholesterol reduction with bococizumab and cardiovascular outcomes.N. Engl. J. Med.2017376161427143710.1056/NEJMoa170148828304242
     [Google Scholar]
  28. BallantyneC.M. BanachM. ManciniG.B. Efficacy and safety of bempedoic acid in patients with statin intolerance.J. Am. Heart Assoc.202097e01626210.1161/JAHA.119.016262
     [Google Scholar]
  29. SabatineM.S. LeiterL.A. WiviottS.D. Cardiovascular safety and efficacy of inclisiran in patients with elevated LDL cholesterol levels.Eur. Heart J.202041211939194910.1093/eurheartj/ehaa407
     [Google Scholar]
  30. CohenJ. PertsemlidisA. KotowskiI.K. GrahamR. GarciaC.K. HobbsH.H. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.Nat. Genet.200537216116510.1038/ng150915654334
     [Google Scholar]
  31. NavareseE.P. RobinsonJ.G. KowalewskiM. KolodziejczakM. AndreottiF. BlidenK. TantryU. KubicaJ. RaggiP. GurbelP.A. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering.JAMA2018319151566157910.1001/jama.2018.252529677301
     [Google Scholar]
  32. KhanS.U. RiazH. RahmanH. KhanM.U. KhanM.S. AlkhouliM. KaluskiE. LeuckerT.M. BlahaM.J. Association of baseline LDL-C with total and cardiovascular mortality in patients using proprotein convertase subtilisin-kexin type 9 inhibitors: A systematic review and meta-analysis.J. Clin. Lipidol.201913453854910.1016/j.jacl.2019.05.01431278046
     [Google Scholar]
  33. RosensonR.S. HegeleR.A. FazioS. The future of PCSK9 inhibitors.Curr. Atheroscler. Rep.20212372910.1007/s11883‑021‑00918‑z
     [Google Scholar]
  34. CannonC.P. BlazingM.A. GiuglianoR.P. McCaggA. WhiteJ.A. TherouxP. DariusH. LewisB.S. OphuisT.O. JukemaJ.W. De FerrariG.M. RuzylloW. De LuccaP. ImK. BohulaE.A. ReistC. WiviottS.D. TershakovecA.M. MuslinerT.A. BraunwaldE. CaliffR.M. Ezetimibe is added to statin therapy after acute coronary syndromes.N. Engl. J. Med.2015372252387239710.1056/NEJMoa141048926039521
     [Google Scholar]
  35. WongN.D. YoungD. ZhaoY. Statin use and attainment of low-density lipoprotein cholesterol goals in high-risk patients with dyslipidemia.J. Clin. Lipidol.201711364966210.1016/j.jacl.2017.02.009
     [Google Scholar]
  36. LandmesserU. ChapmanM.J. StockJ.K. PCSK9 inhibition in patients with dyslipidemia.Circ. Res.2019124175277010.1161/CIRCRESAHA.116.316293
     [Google Scholar]
  37. GencerB. KoskinasK.C. RäberL. PCSK9 inhibitors in clinical practice: What the cardiologist needs to know.Eur. Heart J.202142110011210.1093/eurheartj/ehaa825
     [Google Scholar]
  38. MoriartyP.M. McKenneyJ.M. KoschinskyM.L. Lipoprotein(a) and cardiovascular disease: Current and future therapies.J. Clin. Lipidol.202216215016510.1016/j.jacl.2022.01.009
     [Google Scholar]
  39. NichollsS.J. PuriR. WolskiK. Impact of PCSK9 inhibition with evolocumab on coronary plaque composition.Eur. Heart J.201839131269127810.1093/eurheartj/ehx79929618033
     [Google Scholar]
  40. HaoQ. AertgeertsB. GuyattG. BekkeringG.E. VandvikP.O. KhanS.U. RodondiN. JacksonR. RenyJ.L. Al AnsaryL. Van DrielM. AssendelftW.J.J. AgoritsasT. SpencerF. SiemieniukR.A.C. LytvynL. HeenA.F. ZhaoQ. RiazI.B. RamaekersD. OkwenP.M. ZhuY. DawsonA. OvidiuM.C. VanbrabantW. LiS. DelvauxN. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: A clinical practice guideline with risk-stratified recommendations.BMJ2022377e06906610.1136/bmj‑2021‑06906635508320
     [Google Scholar]
  41. HigginsJ.P.T. AltmanD.G. GøtzscheP.C. JüniP. MoherD. OxmanA.D. SavovicJ. SchulzK.F. WeeksL. SterneJ.A.C. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials.BMJ2011343oct18 2d592810.1136/bmj.d592822008217
     [Google Scholar]
  42. ManagerR. Welcome to RevMan 5.42020Available from: https://training.cochrane.org/system/files/uploads/protected_file/RevMan5.4_user_guide.pdf
  43. HaddawayN.R. PageM.J. PritchardC.C. McGuinnessL.A. PRISMA2020 : An R package and Shiny app for producing PRISMA 2020‐compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis.Campbell Syst. Rev.2022182e123010.1002/cl2.123036911350
     [Google Scholar]
  44. NichollsS.J. KataokaY. NissenS.E. PratiF. WindeckerS. PuriR. HuckoT. AradiD. HerrmanJ.P.R. HermanidesR.S. WangB. WangH. ButtersJ. Di GiovanniG. JonesS. PompiliG. PsaltisP.J. Effect of evolocumab on coronary plaque phenotype and burden in Statin-Treated Patients following myocardial infarction.JACC Cardiovasc. Imaging20221571308132110.1016/j.jcmg.2022.03.00235431172
     [Google Scholar]
  45. HaoY. YangY. WangY. LiJ. Effect of the early application of evolocumab on blood lipid profile and cardiovascular prognosis in patients with extremely high-risk acute coronary syndrome.Int. Heart J.202263466967710.1536/ihj.22‑05235831153
     [Google Scholar]
  46. MehtaS.R. PareG. LonnE.M. JollyS.S. NatarajanM.K. Pinilla-EcheverriN. SchwalmJ.D. ShethT.N. SibbaldM. TsangM. ValettasN. VelianouJ.L. LeeS.F. FerdousT. NaumanS. NguyenH. McCreadyT. McQueenM.J. Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: A randomised, double-blind, sham-controlled trial.EuroIntervention20221811e888e89610.4244/EIJ‑D‑22‑0073536349701
     [Google Scholar]
  47. RaalF. DurstR. BiR. TalloczyZ. MaheuxP. LesogorA. KasteleinJ.J.P. Efficacy, safety, and tolerability of Inclisiran in patients with homozygous familial hypercholesterolemia: Results from the ORION-5 randomized clinical trial.Circulation2024149535436210.1161/CIRCULATIONAHA.122.06346037850379
     [Google Scholar]
  48. SchwartzG.G. SzarekM. BittnerV.A. DiazR. GoodmanS.G. JukemaJ.W. LandmesserU. López-JaramilloP. ManvelianG. PordyR. ScemamaM. SinnaeveP.R. WhiteH.D. Gabriel StegP. Lipoprotein(A) and benefit of PCSK9 inhibition in patients with nominally controlled LDL cholesterol.J. Am. Coll. Cardiol.202178542143310.1016/j.jacc.2021.04.10234325831
     [Google Scholar]
  49. AlbostaM.S. GrantJ.K. TaubP. BlumenthalR.S. MartinS.S. MichosE.D. Inclisiran: A new strategy for LDL-C lowering and prevention of atherosclerotic cardiovascular disease.Vasc. Health Risk Manag.20231942143110.2147/VHRM.S33842437434791
     [Google Scholar]
  50. GaoF. WangZ.J. MaX.T. ShenH. YangL.X. ZhouY.J. Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography.Lipids Health Dis.202120110610.1186/s12944‑021‑01528‑334511134
     [Google Scholar]
  51. RexhajE. BärS. SoriaR. UekiY. HänerJ.D. OtsukaT. KavaliauskaiteR. SiontisG.C.M. StorteckyS. ShibutaniH. SpirkD. EngstrømT. LangI. MorfL. AmbühlM. WindeckerS. LosdatS. KoskinasK.C. RäberL. Effects of alirocumab on endothelial function and coronary atherosclerosis in myocardial infarction: A PACMAN-AMI randomized clinical trial substudy.Atherosclerosis202439211750410.1016/j.atherosclerosis.2024.11750438513436
     [Google Scholar]
  52. JanikM.J. UrbachD.V. van NieuwenhuizenE. ZhaoJ. YellinO. Baccara-DinetM.T. PordyR. ManvelianG. Alirocumab treatment and neurocognitive function according to the CANTAB scale in patients at increased cardiovascular risk: A prospective, randomized, placebo-controlled study.Atherosclerosis2021331202710.1016/j.atherosclerosis.2021.06.91334303265
     [Google Scholar]
  53. SchwartzG.G. StegP.G. SzarekM. BhattD.L. BittnerV.A. DiazR. EdelbergJ.M. GoodmanS.G. HanotinC. HarringtonR.A. JukemaJ.W. LecorpsG. MahaffeyK.W. MoryusefA. PordyR. QuinteroK. RoeM.T. SasielaW.J. TambyJ.F. TricociP. WhiteH.D. ZeiherA.M. Alirocumab and cardiovascular outcomes after acute coronary syndrome.N. Engl. J. Med.2018379222097210710.1056/NEJMoa180117430403574
     [Google Scholar]
  54. BanachM. RizzoM. NikolicD. Statin intolerance – An attempt to resolve one of the most important issues in cardiology.Int. J. Cardiol.201521112813510.1016/j.ijcard.2015.05.124
     [Google Scholar]
  55. PuriR. NissenS.E. ShaoM. Impact of statins on coronary atheroma progression.JAMA2014311323324310.1001/jama.2013.28254224430308
     [Google Scholar]
  56. FerenceB.A. GinsbergH.N. GrahamI. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 2. Mechanistic insights from genetic studies.Eur. Heart J.201738322469247710.1093/eurheartj/ehx14428444290
     [Google Scholar]
  57. BallantyneC.M. BanachM. ManciniG.B. Safety and efficacy of PCSK9 inhibitors.Nat. Rev. Cardiol.2021182889010.1038/s41569‑021‑00462‑0
     [Google Scholar]
  58. TothP.P. BanachM. FarnierM. PCSK9 inhibition in high-risk cardiovascular patients.Cardiol. Clin.202038111512810.1016/j.ccl.2019.08.00731753170
     [Google Scholar]
  59. WangX. WenD. ChenY. MaL. YouC. PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: A bayesian network meta-analysis.Cardiovasc. Diabetol.202221110710.1186/s12933‑022‑01542‑435706032
     [Google Scholar]
  60. AliR. BanachM. WongN.D. Global burden of dyslipidemia.Circulation2019139656657810.1161/CIRCULATIONAHA.118.038639
     [Google Scholar]
  61. GrundyS.M. CleemanJ.I. MerzC.N.B. BrewerH.B.Jr ClarkL.T. HunninghakeD.B. PasternakR.C. SmithS.C.Jr StoneN.J. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines.Circulation2004110222723910.1161/01.CIR.0000133317.49796.0E15249516
     [Google Scholar]
  62. CannonC.P. BlazingM.A. GiuglianoR.P. Adding ezetimibe to statin therapy improves cardiovascular outcomes.Circulation2015131221969197010.1161/CIR.0000000000000186
     [Google Scholar]
  63. LaufsU. DescampsO.S. CatapanoA.L. Practical recommendations for the use of PCSK9 inhibitors in clinical practice: Translating guidelines into practice.Cardiovasc. Drugs Ther.202034111010.1007/s10557‑019‑06925‑z32034644
     [Google Scholar]
  64. LandmesserU. ChapmanM.J. FarnierM. LDL-cholesterol lowering beyond statins: The PCSK9 inhibitor era.Eur. Heart J.201738362943294910.1093/eurheartj/ehx382
     [Google Scholar]
  65. GiuglianoR.P. PedersenT.R. ParkJ.G. Baseline lipoprotein(a) and clinical outcomes with PCSK9 inhibition in Fourier.Circulation2018138141550155910.1161/CIRCULATIONAHA.118.035909
     [Google Scholar]
  66. BanachM. SerbanM.C. SahebkarA. Impact of statin therapy on plasma coenzyme Q10 concentrations: A systematic review and meta-analysis.Mayo Clin. Proc.2015901243410.1016/j.mayocp.2014.08.02125440725
     [Google Scholar]
  67. KoskinasK.C. SiontisG.C.M. PiccoloR. Efficacy and safety of low-density lipoprotein cholesterol lowering by PCSK9 inhibition: An analysis of patient-level data.Lancet20183911012664165110.1016/S0140‑6736(17)32337‑5
     [Google Scholar]
  68. CannonC.P. StegP.G. SzarekM. Alirocumab in patients after acute coronary syndrome.N. Engl. J. Med.2015372252387239710.1056/NEJMoa141048926039521
     [Google Scholar]
  69. BaigentC. KeechA. KearneyP.M. BlackwellL. BuckG. PollicinoC. KirbyA. SourjinaT. PetoR. CollinsR. SimesR. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins.Lancet200536694931267127810.1016/S0140‑6736(05)67394‑116214597
     [Google Scholar]
  70. MihaylovaB. EmbersonJ. BlackwellL. KeechA. SimesJ. BarnesE.H. VoyseyM. GrayA. CollinsR. BaigentC. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials.Lancet2012380984158159010.1016/S0140‑6736(12)60367‑522607822
     [Google Scholar]
  71. CollinsR. ArmitageJ. ParishS. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebocontrolled trial.Lancet2002360932672210.1016/S0140‑6736(02)09327‑312114036
     [Google Scholar]
  72. FulcherJ. O’ConnellR. VoyseyM. EmbersonJ. BlackwellL. MihaylovaB. SimesJ. CollinsR. KirbyA. ColhounH. BraunwaldE. La RosaJ. PedersenT.R. TonkinA. DavisB. SleightP. FranzosiM.G. BaigentC. KeechA. Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174 000 participants in 27 randomised trials.Lancet201538599761397140510.1016/S0140‑6736(14)61368‑425579834
     [Google Scholar]
  73. DugréN. LindbladA.J. PerryD. AllanG.M. BraschiÉ. FalkJ. FroentjesL. GarrisonS.R. KirkwoodJ.E.M. KorownykC.S. McCormackJ.P. MoeS.S. PaigeA. PotterJ. ThomasB.S. TonJ. YoungJ. WereschJ. KolberM.R. Lipid-lowering therapies for cardiovascular disease prevention and management in primary care: PEER umbrella systematic review of systematic reviews.Can. Fam. Physician2023691070171110.46747/cfp.691070137833094
     [Google Scholar]
  74. OikonomouE.K. PsaltopoulouT. GeorgiopoulosG. Lipid-lowering agents beyond statins: Meta-analysis and meta-regression of randomized controlled trials.J. Am. Coll. Cardiol.202075121496150710.1016/j.jacc.2020.01.045
     [Google Scholar]
  75. SabatineM.S. GiuglianoR.P. KeechA.C. HonarpourN. WiviottS.D. MurphyS.A. KuderJ.F. WangH. LiuT. WassermanS.M. SeverP.S. PedersenT.R. Evolocumab and clinical outcomes in patients with cardiovascular disease.N. Engl. J. Med.2017376181713172210.1056/NEJMoa161566428304224
     [Google Scholar]
  76. CannonC.P. BlazingM.A. GiuglianoR.P. McCaggA. WhiteJ.A. TherouxP. DariusH. LewisB.S. OphuisT.O. JukemaJ.W. De FerrariG.M. RuzylloW. De LuccaP. ImK. BohulaE.A. ReistC. WiviottS.D. TershakovecA.M. MuslinerT.A. BraunwaldE. CaliffR.M. Ezetimibe added to statin therapy after acute coronary syndromes.N. Engl. J. Med.2015372252387239710.1056/NEJMoa141048926039521
     [Google Scholar]
  77. BhattD.L. StegP.G. MillerM. BrintonE.A. JacobsonT.A. KetchumS.B. DoyleR.T.Jr JulianoR.A. JiaoL. GranowitzC. TardifJ.C. BallantyneC.M. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia.N. Engl. J. Med.20193801112210.1056/NEJMoa181279230415628
     [Google Scholar]
  78. MoriartyP.M. CannonC.P. TothP.P. Inclisiran for LDL cholesterol reduction: A pooled analysis of phase 3 trials.J. Am. Coll. Cardiol.20217791182119010.1016/j.jacc.2021.01.01633663735
     [Google Scholar]
  79. ColhounH.M. GinsbergH.N. RobinsonJ.G. Inclisiran and cardiovascular event reduction in patients with elevated lipoprotein(a): Analysis of the ORION-4 trial.Lancet2021398103031403141010.1016/S0140‑6736(21)01235‑1
     [Google Scholar]
  80. TothP.P. PhilipS. HullM. GranowitzC. Elevated lipoprotein(a) and the efficacy of PCSK9 inhibition with alirocumab: Insights from ODYSSEY OUTCOMES.Circulation2020141201605161410.1161/CIRCULATIONAHA.119.045183
     [Google Scholar]
  81. KoskinasK.C. RäberL. WindeckerS. PCSK9 inhibitors for secondary prevention in patients with cardiovascular disease: A Bayesian meta-analysis.Cardiovasc. Diabetol.202019111110.1186/s12933‑020‑01090‑132646432
     [Google Scholar]
/content/journals/ccr/10.2174/011573403X345749250122092324
Loading
The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis
Curr. Cardiol. Rev. 21, E1573403X345749 (2025); https://doi.org/10.2174/011573403X345749250122092324
/content/journals/ccr/10.2174/011573403X345749250122092324
/content/journals/ccr/10.2174/011573403X345749250122092324
Loading

Data & Media loading...

Supplements

PRISMA checklist is available as supplementary material on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): atherosclerotic cardiovascular disease; cardiovascular risk reduction; ezetimibe; LDL cholesterol reduction; lipid-lowering agents; major adverse cardiovascular events; PCSK9 inhibitors; statin therapy

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test